参考文献/References:
[1] 李 喆,郭 帅,叶蕴青,等.中国中重度主动脉瓣疾病患者的临床特点及预后:来自China-VHD研究的分析[J].中国循环杂志,2022,37:322-328.
Li Z,Guo S,Ye YQ,et al.Clinical characteristics and prognosis of Chinese patients with moderate to severe aortic valve disease:Analysis from the China-VHD study[J].Chin Circul J,2022,37:322-328.
[2]韩康宁,马晓腾,杜 俣,等.中国人群主动脉瓣狭窄的特点[J].心肺血管病杂志,2021,40:990-991.
Han KN,Ma XT,Du Y,et al.Characteristics of aortic stenosis in the Chinese population[J].J Cardiopulm Dis,2021,40:990-991.
[3] 牛毅菲,贺 宇,黄 琼,等.经皮冠状动脉介入治疗联合经导管主动脉瓣置换术治疗冠心病合并主动脉瓣疾病的临床疗效[J].中国心血管病研究,2023,21:263-268.
Niu YF,He Y,Huang Q,et al.Clinical efficacy of percutaneous coronary intervention combined with transcatheter aortic valve replacement for coronary heart disease complicated with aortic valve disease[J].Chin J Cardiovasc Dis Res,2023,21:263-268.
[4]国家心血管病中心,国家结构性心脏病介入质控中心,中华医学会心血管病学分会,等.经导管主动脉瓣置换术临床实践指南[J].中华医学杂志,2023,103:886-900.
National Center for Cardiovascular Diseases,National Structural Heart Disease Intervention Quality Control Center,Chinese Medical Association Society of Cardiology,et al.Clinical practice guidelines for transcatheter aortic valve replacement[J].Natl Med J China,2023,103:886-900.
[5]Worthington KP,Giannantonio E.Implementing a nurse-driven early ambulation protocol to enhance post-transcatheter aortic valve replacement outcomes:a quality improvement initiative[J].J Nurs Care Qual,2025,40:187-192.
[6]Tang GHL,Zaid S,De Backer O.Navigating the landscape of reinterventions after TAVR[J].J Am Coll Cardiol,2025,85:908-911.
[7]Wei G,Tan J,Ma F,et al.Barriers and facilitators of the nurse providing evidence-based preoperative visit-care for transcatheter aortic valve replacement:a mixed-methods study based on an evidence application setting[J].BMC Health Serv Res,2024,24:1101.
[8]Tan J,Wei G,Ma F,et al.Preoperative visit-care for transcatheter aortic valve replacement:a review[J].BMC Cardiovasc Disord,2024,24:573.
[9]Holloway J,Lee M,Stephens B,et al.Anesthetic management of intracardiac migration of medical devices[J].J Cardiothorac Vasc Anesth,2024.
[10]李柄辉,訾 豪,李路遥,等.医学领域一次研究和二次研究的方法学质量(偏倚风险)评价工具[J].医学新知,2021,31:51-58.
Li BH,Zi H,Li LY,et al.Evaluation tools for methodological quality of primary and secondary studies in the medical field[J].Med New Knowl,2021,31:51-58.
[11]Shea BJ,Reeves BC,Wells G,et al.AMSTAR 2:a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions,or both[J].BMJ,2017,358:j4008.
[12]王春青,胡 雁.JBI证据预分级及证据推荐级别系统[J].护士进修杂志,2015,30:964-967.
Wang CQ,Hu Y.JBI evidence pre-grading and evidence recommendation level system[J].J Nurs Adv,2015,30:964-967.
[13]科学医学会协会.结构化共识构建.[EB/OL].https:∥www.awmf.org/regelwerk/strukturierte-konsensfindung,2025-05-11.
Scientific Medical Association.Structured consensus building[EB/OL].https:∥www.awmf.org/regelwerk/strukturierte-konsensfindung,2025-05-11.
[14]Cantey C.Treatment disparities in severe aortic stenosis with TAVR[J].Nurse Pract,2024,49:13-15.
[15]Jia YY,Guo ZT,Zhang YP,et al.Development of a complex intervention to prevent complications in patients recovering at home after transcatheter aortic valve replacement by optimizing home-based cardiac rehabilitation processes:a Delphi study[J].Front Public Health,2024,12:1491311.
[16]Bowdish ME,Habib RH,Kaneko T,et al.Cardiac surgery after transcatheter aortic valve replacement:trends and outcomes[J].Ann Thorac Surg,2024,118:155-162.
[17]Nagasaka T,Patel V,Koren O,et al.TAVR-in-TAVR with a balloon-expandable valve for paravalvular leak[J].Front Cardiovasc Med,2024,11:1374078.
[18]Atkins MD,Reardon MJ.What did the transcatheter aortic valve replacement-surgical aortic valve replacement trials tell us?[J].Ann Cardiothorac Surg,2024,13:206-210.
[19]Puehler T,Pommert NS,Freitag-Wolf S,et al.Tricuspid regurgitation and TAVR:outcomes,risk factors and biomarkers[J].J Clin Med,2024,13.
[20]Imamura T,Izumida T,Onoda H,et al.Trajectory of pulmonary congestion during TAVR[J].Cardiovasc Interv Ther,2024,39:183-190.
[21]Kermanshahchi J,Thind B,Davoodpour G,et al.Transcatheter aortic valve replacement versus surgical aortic valve replacement:a review on the length of stay,cost,comorbidities,and procedural complications[J].Cureus,2024,16:e54435.
[22]中国医师协会心血管内科医师分会结构性心脏病学组.单纯主动脉瓣反流经股动脉主动脉瓣置换中国专家共识2023[J].中国介入心脏病学杂志,2023,31:801-809.
Structural Heart Disease Group of Chinese College of Cardiovascular Physician.Chinese expert consensus on trans-femoral transcatheter aortic valve replacement for pure aortic regurgitation 2023[J].Chin J Intervent Cardiol,2023,31:801-809.
[23]Tang GHL,Zaid S,Kleiman NS,et al.Explant vs Redo-TAVR after transcatheter valve failure:mid-term outcomes from the EXPLANTORREDO-TAVR international registry[J].JACC Cardiovasc Interv,2023,16:927-941.
[24]Galhardo A,Avvedimento M,Mengi S,et al.Redo-TAVR:Essential Concepts,Updated Data and Current Gaps in Evidence[J].J Clin Med,2023,12.
[25]Meier D,Tzimas G,Akodad M,et al.TAVR in TAVR:Where are we in 2023 for management of failed TAVR valves?[J].Curr Cardiol Rep,2023,25:1425-1431.
[26]Faroux L,Villecourt A,Metz D.The management of coronary artery disease in TAVR patients[J].J Clin Med,2023,12.
[27]Topalkatti U,Prasad RC,Koppu BR,et al.Comparative analysis of TAVR and surgical valve replacement for low-risk patients[J].Cureus,2023,15:e47234.
[28]Krishnaswamy A.Optimizing valve-in-valve TAVR:should a low gradient alone receive high marks?[J].JACC Cardiovasc Interv,2023,16:3013-3015.
[29]Cavanaugh S,Amirjamshidi H,Hisamoto K.Navigating the unexpected:iatrogenic aortic injuries during transcatheter aortic valve replacement[J].J Clin Med,2023,12.
[30]Kermanshahchi J,Thind B,Davoodpour G,et al.A review of the cost effectiveness of transcatheter aortic valve replacement versus surgical aortic valve replacement[J].Cureus,2023,15:e46535.
[31]Improta R,Di Pietro G,Kola N,et al.A Meta-analysis of short-term outcomes of TAVR versus SAVR in bicuspid aortic valve stenosis and TAVR results in different bicuspid valve anatomies[J].J Clin Med,2023,12:7371.
[32]Annie FH,Belcher AM,Manivannan PKR,et al.Impact of TAVR on patients with severe aortic stenosis and liver cirrhosis[J].Am J Physiol Heart Circ Physiol,2023,325:H539-H544.
[33]丰德京,吴永健.主动脉瓣狭窄患者治疗的终生策略[J].中国循环杂志,2022,37:1276-1280.
Feng DJ,Wu YJ.Lifelong treatment strategies for patients with aortic stenosis[J].Chin Circul J,2022,37:1276-1280.
[34]许富康,何益平,郭航远,等.经导管主动脉瓣置换术治疗主动脉瓣狭窄应用进展[J].介入放射学杂志,2022,31:1020-1026.
Xu FK,He YP,Guo HY,et al.Advances in the application of transcatheter aortic valve replacement for aortic stenosis[J].J Intervent Radiol,2022,31:1020-1026.
[35]Guida P,Mastro F,Scrascia G,et al.Performance of the european system for cardiac operative risk evaluation Ⅱ:a meta-analysis of 22 studies involving 145 592 cardiac surgery procedures[J].J Thorac Cardiovasc Surg,2014,148:3049-3057.
[36]吴丽映,陈海生,李 彬,等.经导管主动脉瓣膜置换术在重症主动脉瓣膜病中的临床应用[J].中国心血管病研究,2021,19:31-35.
Wu LY,Chen HS,Li B,et al.Clinical application of transcatheter aortic valve replacement in severe aortic valve disease[J].Chin J Cardiovasc Dis Res,2021,19:31-35.
[37]潘文志,龙愉良,周达新,等.2020年经导管瓣膜治疗主要进展[J].中国胸心血管外科临床杂志,2021,28:371-375.
Pan WZ,Long YL,Zhou DX,et al.Main progress in transcatheter valve therapy in 2020[J].Chin J Thorac Cardiovasc Surg,2021,28:371-375.
[38]党梦秋,范嘉祺,朱齐丰,等.《经导管主动脉瓣置换术中国专家共识(2020更新版)》解读[J].心电与循环,2021,40:1-5.
Dang MQ,Fan JQ,Zhu QF,et al.Interpretation of “Expert Consensus on Transcatheter Aortic Valve Replacement in China”[J].Electrocardiol Circ,2021,40:1-5.
[39]毛 越,梁江淑渊,张玉萍,等.经导管主动脉瓣置换术患者Ⅰ期心脏康复的最佳证据总结[J].中华急危重症护理杂志,2021,2:232-237.
Mao Y,Liang JSY,Zhang YP,et al.Best evidence summary of phase Ⅰ cardiac rehabilitation for patients undergoing transcatheter aortic valve replacement[J].Chin J Crit Emerg Nurs,2021,2:232-237.
[40]中国结构性心脏病介入治疗进展报告编写组.中国结构性心脏病介入治疗进展报告2020[J].中国循环杂志,2021,36:833-840.
Annual Report Committee for Progress of Interventional Therapy of Structural Heart Disease in China.2020 Report on the Progress of Interventional Therapy for Structural Heart Disease in China[J].Chin Circul J,2021,36:833-840.
[41]张 倩,王墨扬,吴永健.《经导管主动脉瓣置换术中国专家共识(2020更新版)》解读[J].华西医学,2021,36:1191-1195.
Zhang Q,Wang MY,Wu YJ.Interpretation of the “Expert Consensus on Transcatheter Aortic Valve Replacement in China”[J].West China Med J,2021,36:1191-1195.
[42]李 捷,孙英皓,李 光,等.经动脉入路经导管主动脉瓣置换术治疗单纯主动脉瓣反流的初步经验[J].中国介入心脏病学杂志,2021,29:678-683.
Li J,Sun YH,Li G,et al.Preliminary experience of transcatheter aortic valve replacement for isolated aortic valve regurgitation via arterial approach[J].Chin J Intervent Cardiol,2021,29:678-683.
[43]Trauzeddel RF,Nordine M,Balanika M,et al.Current anesthetic care of patients undergoing transcatheter aortic valve replacement in Europe:results of an online survey[J].J Cardiothorac Vasc Anesth,2021,35:1737-1746.
[44]Avvedimento M,Tang GHL.Transcatheter aortic valve replacement:Recent updates[J].Prog Cardiovasc Dis,2021,69:73-83.
[45]Mach M,Okutucu S,Kerbel T,et al.Vascular complications in TAVR:incidence,clinical impact,and management[J].J Clin Med,2021,10:5046.
[46]Baro R,Cura F,Belardi J,et al.Surgical risk scoring in TAVR:still needed? A metaregression analysis[J].Curr Probl Cardiol,2021,46:100875.
[47]Sandhu A,Tzou WS.A disruptive technology:determining need for permanent pacing after TAVR[J].Curr Cardiol Rep,2021,23:53.
[48]Sammour Y,Krishnaswamy A,Kumar A,et al.Incidence,predictors,and implications of permanent pacemaker requirement after transcatheter aortic valve replacement[J].JACC Cardiovasc Interv,2021,14:115-134.
[49]Fliegner MA,Sukul D,Thompson MP,et al.Evaluating treatment-specific post-discharge quality-of-life and cost-effectiveness of TAVR and SAVR:Current practice & future directions[J].Int J Cardiol Heart Vasc,2021,36:100864.
[50]Price J,Bob-Manuel T,Tafur J,et al.Transaxillary TAVR leads to shorter ventilator duration and hospital length of stay compared to transapical TAVR[J].Curr Probl Cardiol,2021,46:100624.
[51]中华医学会心血管病学分会结构性心脏病学组.经导管主动脉瓣置换术治疗二叶式主动脉瓣狭窄的中国专家建议[J].中华心血管病杂志,2020,48:634-640.
Chinese Medical Association Society of Cardiology Structural Heart Disease Group.Chinese expert recommendations for transcatheter aortic valve replacement for bicuspid aortic valve stenosis[J].Chin J Cardiovasc Dis,2020,48:634-640.
[52]周达新,潘文志,吴永健,等.经导管主动脉瓣置换术中国专家共识(2020更新版)[J].中国介入心脏病学杂志,2020,28:301-309.
Zhou DX,Pan WZ,Wu YJ,et al.Expert Consensus on Transcatheter Aortic Valve Replacement in China[J].Chin J Intervent Cardiol,2020,28:301-309.
[53]李光照,王明蛟,胡彩娜,等.经导管主动脉瓣置换术治疗重度主动脉瓣狭窄的初步临床疗效分析[J].临床心血管病杂志,2020,36:280-283.
Li GZ,Wang MJ,Hu CN,et al.Preliminary clinical efficacy analysis of transcatheter aortic valve replacement for severe aortic stenosis[J].J Clin Cardiovasc Dis,2020,36:280-283.
[54]郭 帅,张 斌,吴永健.经导管主动脉瓣置换术的最新进展[J].中国医刊,2020,55:4-7.
Guo S,Zhang B,Wu YJ.Recent advances in transcatheter aortic valve replacement[J].Chin Med J,2020,55:4-7.
[55]Cormican D,Jayaraman A,Villablanca P,et al.TAVR procedural volumes and patient outcomes:analysis of recent data[J].J Cardiothorac Vasc Anesth,2020,34:545-550.
[56]Veulemans V,Afzal S,Papadopoulos G,et al.TAVR-related echocardiographic assessment-status quo,challenges and perspectives[J].Acta Cardiol,2020,75:275-285.
[57]Gheorghe L,Brouwer J,Gutierrez A,et al.Can TAVR be effectively and safely performed without intraprocedural TEE?[J].Curr Cardiol Rep,2020,22:80.
[58]Grube E,Sinning J.Simplify TAVR?:To Pre-Dilate,or Not to Pre-Dilate,That Is the Question[J].JACC Cardiovasc Interv,2020,13:603-605.
[59]Cubero-Gallego H,Dam C,Meca J,et al.Transcatheter aortic valve replacement:expanding indications to low-risk patients[J].Ann Transl Med,2020,8:960.
[60]Pasic M.Annular Rupture During TAVR:Despite It,Dr.Alain Cribier Should Receive a Nobel Prize[J].JACC Cardiovasc Interv,2020,13:1800-1802.
[61]Mc Morrow R,Kriza C,Urbán P,et al.Assessing the safety and efficacy of TAVR compared to SAVR in low-to-intermediate surgical risk patients with aortic valve stenosis:An overview of reviews[J].Int J Cardiol,2020,314:43-53.
[62]De Backer O,Landes U,Fuchs A,et al.Coronary access after TAVR-in-TAVR as evaluated by multidetector computed tomography[J].JACC Cardiovasc Interv,2020,13:2528-2538.
[63]冯晔子,张申伟,马倩倩,等.主动脉瓣重度狭窄经导管主动脉瓣置换术后患者围术期效果观察[J].心肺血管病杂志,2019,38:1146-1149.
Feng YZ,Zhang SW,Ma QQ,et al.Perioperative outcomes of patients with severe aortic stenosis after transcatheter aortic valve replacement[J].J Cardiopulm Dis,2019,38:1146-1149.
[64]林心平,王建安.中国心脏瓣膜病介入治疗的现状与进展[J].心电与循环,2019,38:353-356.
Lin XP,Wang JA.Current status and progress of interventional treatment for valvular heart disease in China[J].Electrocardiol Circ,2019,38:353-356.
[65]吴永健,王 媛.经导管主动脉瓣置换术治疗的新时代:PARTNER 3临床试验的启示[J].中国循环杂志,2019,34:632-634.
Wu YJ,Wang Y.A new era of transcatheter aortic valve replacement:Insights from the PARTNER 3 clinical trial[J].Chin Circul J,2019,34:632-634.
[66]孟庆童,黄 靖,李 源,等.主动脉瓣重度狭窄患者经导管主动脉瓣膜置换术后生活质量现状及影响因素分析[J].中华现代护理杂志,2019:2535-2539.
Meng QT,Huang J,Li Y,et al.Current status and influencing factors of quality of life in patients with severe aortic stenosis after transcatheter aortic valve replacement[J].Chin J Mod Nurs,2019:2535-2539.
[67]张 倩,王建德,肖明虎,等.经导管主动脉瓣置换术后老年主动脉瓣重度狭窄患者左心室重构特征及影响因素分析[J].中华老年心脑血管病杂志,2019,21:683-686.
Zhang Q,Wang JD,Xiao MH,et al.Characteristics and influencing factors of left ventricular remodeling in elderly patients with severe aortic stenosis after transcatheter aortic valve replacement[J].Chin J Geriatr Cardiovasc Cerebrovasc Dis,2019,21:683-686.
[68]牛冠男,宋光远,王墨扬,等.高危重度主动脉瓣狭窄经颈动脉途径行经导管主动脉瓣置换术治疗的安全性和有效性[J].中华老年心脑血管病杂志,2019,21:687-690.
Niu GN,Song GY,Wang MY,et al.Safety and efficacy of transcatheter aortic valve replacement via carotid artery approach for high-risk severe aortic stenosis[J].Chin J Geriatr Cardiovasc Cerebrovasc Dis,2019,21:687-690.
[69]许海燕,于子凯,齐喜玲,等.经导管主动脉瓣置换术序贯综合康复的探索和体会[J].中华老年心脑血管病杂志,2019,21:699-702.
Xu HY,Yu ZK,Qi XL,et al.Exploration and experience of sequential comprehensive rehabilitation after transcatheter aortic valve replacement[J].Chin J Geriatr Cardiovasc Cerebrovasc Dis,2019,21:699-702.
[70]唐 红.《TAVR围术期超声心动图检查专家共识》解读[J].西部医学,2019,31:497-502.
Tang H.Interpretation of the “Expert Consensus on Perioperative Echocardiography in TAVR”[J].West China Med J,2019,31:497-502.
[71]王 玺,李怡坚,欧袁伟翔,等.经导管主动脉瓣置换术中Venus A-Valve与进口瓣膜临床应用的比较[J].华西医学,2019,34:379-384.
Wang X,Li YJ,Ou YWX,et al.Comparison of clinical application of Venus A-Valve and imported valves in transcatheter aortic valve replacement[J].West China Med J,2019,34:379-384.
[72]杨力凡,潘文志,张晓春,等.单中心100例经导管主动脉瓣置换结果分析[J].复旦学报,2019,46:238-242.
Yang LF,Pan WZ,Zhang XC,et al.Analysis of 100 cases of transcatheter aortic valve replacement in a single center[J].Fudan Univ J Med Sci,2019,46:238-242.
[73]梁 影,管玉龙.经导管主动脉瓣置换术临床应用现状及进展[J].心肺血管病杂志,2019,38:104-108.
Liang Y,Guan YL.Current status and progress of clinical application of transcatheter aortic valve replacement[J].J Cardiopulm Dis,2019,38:104-108.
[74]Karycki MK.Transcatheter aortic valve replacement[J].Nursing,2019,49:24-31.
[75]Droppa M,Borst O,Katzenberger T,et al.Comparison of safety and periprocedural complications of transfemoral aortic valve replacement under local anaesthesia:minimalist versus complete Heart Team[J].EuroIntervention,2019,14:e1819-e1825.
[76]Bana A.TAVR-present,future,and challenges in developing countries[J].Indian J Thorac Cardiovasc Surg,2019,35:473-484.
[77]Davidson LJ,Davidson CJ.CAD strategy in the TAVR era[J].Catheter Cardiovasc Interv,2019,93:553-554.
[78]Siddique S,Gada H,Mumtaz MA,et al.Should all low-risk patients now be considered for TAVR? operative risk,clinical,and anatomic considerations[J].Curr Cardiol Rep,2019,21:161.
[79]White K,Macfarlane H,Hoffmann B,et al.Consensus statement of standards for interventional cardiovascular nursing practice[J].Heart Lung Circ,2018,27:535-551.
[80]Rotman OM,Bianchi M,Ghosh RP,et al.Principles of TAVR valve design,modelling,and testing[J].Expert Rev Med Devices,2018,15:771-791.
[81]Voudris KV,Petropulos P,Karyofillis P,et al.Timing and outcomes of PCI in the TAVR Era[J].Curr Treat Options Cardiovasc Med,2018,20:22.
[82]Satler L,Thourani VH.Who can we save after an intraprocedural catastrophe during TAVR?[J].Catheter Cardiovasc Interv,2018,92:157-158.
[83]Sherwood MW,Vora AN.Challenges in aortic stenosis:review of antiplatelet/anticoagulant therapy management with transcatheter aortic valve replacement:TAVR with recent PCI,TAVR in the patient with atrial fibrillation,and TAVR thrombosis management[J].Curr Cardiol Rep,2018,20:130.
[84]Guedeney P,Mehran R.Non-femoral TAVR:time to stratify alternative vascular approaches[J].Catheter Cardiovasc Interv,2018,92:1194-1195.
[85]O'Malley RG,Mahaffey KW,Fearon WF.Adjuvant antithrombotic therapy in TAVR[J].Curr Cardiol Rep,2017,19:41.
[86]Bajaj A,Pancholy S,Sethi A,et al.Safety and feasibility of PCI in patients undergoing TAVR:a systematic review and meta-analysis[J].Heart Lung,2017,46:92-99.
[87]Mohammadi M,Hill C,Chaney S.Is transcatheter aortic valve replacement a safe treatment for elderly patients with severe aortic valve stenosis?[J].J Am Assoc Nurse Pract,2016,28:387-392.
[88]Block PC,Mack M.If TAVR cannot be transfemoral,then what?[J].JACC Cardiovasc Interv,2016,9:2326-2328.
[89]Gilchrist IC,Hansen J.Between a rock and a hard place:TAVR and ESRD[J].Catheter Cardiovasc Interv,2016,87:1322-1323.
[90]Block PC.Understanding rare comorbidities in TAVR[J].Catheter Cardiovasc Interv,2015,86:895-896.
[91]Zhang P,Melander S.Transcatheter aortic valve replacement for severe aortic stenosis[J].Crit Care Nurs Q,2014,37:346-356.
[92]Speiser B,Dutra-Brice C.Transcatheter aortic valve replacement:establishing a comprehensive program model for hybrid cardiac catheterization laboratories in the department of veterans affairs[J].Dimens Crit Care Nurs,2014,35:262-274.
[93]Contrera P,Cushing M.AANA Journal Course:Update for nurse anesthetists--part-4--transcatheter aortic valve replacement[J].AANA J,2013,81:399-408.
[94]Lauck S,Achtem L,Boone RH,et al.Implementation of processes of care to support transcatheter aortic valve replacement programs[J].Eur J Cardiovasc Nurs,2013,12:35-38.
[95]Quail MA,Taylor AM.Valvular disease.Super size me? Annular size and paravalvular leak after TAVR[J].Nat Rev Cardiol,2012,9:265-266.
[96]朱 丽,徐冰晨,潘文志,等.中国经导管主动脉瓣置换术手术方式、术中使用器械及护理现状调查分析[J].中国胸心血管外科临床杂志,2022,29:238-244.
Zhu L,Xu BC,Pan WZ,et al.Survey and analysis of surgical techniques,intraoperative devices,and nursing practices in transcatheter aortic valve replacement in China[J].Chin J Thorac Cardiovasc Surg,2022,29:238-244.
[97]Kingery DRJ,Roberts A,Horstemeyer D,et al.Complications of TAVR from an anesthesia perspective[J].HCA Healthc J Med,2022,3:225-229.
(收稿日期:2025-10-21)
(本文编辑:谷 珂)